InsiderTrades.com logo

NEUP Insider Trading

Insider Ownership Percentage: 1.50%
Insider Buying (Last 12 Months): $3,285,025.40
Insider Selling (Last 12 Months): $0.00

Neuphoria Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Neuphoria Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neuphoria Therapeutics Share Price & Price History

Current Price: $4.39
Price Change: ▲ Price Increase of +0.08 (1.86%)
As of 02/24/2026 04:59 PM ET

This chart shows the closing price history over time for NEUP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Neuphoria Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/21/2025Lynx1 Capital Management LpMajor ShareholderBuy639,110$5.14$3,285,025.40875,328View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Neuphoria Therapeutics (NASDAQ:NEUP)

15.90% of Neuphoria Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NEUP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Neuphoria Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026XTX Topco Ltd12,008$47K0.0%N/A0.223%Search for SEC Filing on Google Icon
2/18/2026Ikarian Capital LLC47,443$0.18M0.0%N/A0.882%Search for SEC Filing on Google Icon
2/18/2026Boothbay Fund Management LLC14,000$54K0.0%N/A0.260%Search for SEC Filing on Google Icon
2/18/2026Bridgeway Capital Management LLC14,750$57K0.0%N/A0.274%Search for SEC Filing on Google Icon
2/17/2026ADAR1 Capital Management LLC30,000$0.12M0.0%N/A0.558%Search for SEC Filing on Google Icon
2/17/2026Diadema Partners LP50,000$0.19M0.0%+133.1%0.930%Search for SEC Filing on Google Icon
2/17/2026Persistent Asset Partners Ltd13,403$52K0.0%+173.1%0.249%Search for SEC Filing on Google Icon
2/12/2026Commonwealth Equity Services LLC11,207$43K0.0%N/A0.208%Search for SEC Filing on Google Icon
2/10/2026AdvisorShares Investments LLC134,194$0.52M0.1%+129.1%2.494%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC17,303$67K0.0%+33.3%0.322%Search for SEC Filing on Google Icon
1/16/2026FNY Investment Advisers LLC26,500$0.10M0.0%N/A0.493%Search for SEC Filing on Google Icon
11/17/2025Millennium Management LLC18,329$0.22M0.0%N/A0.777%Search for SEC Filing on Google Icon
11/10/2025Persistent Asset Partners Ltd4,908$58K0.0%N/A0.208%Search for SEC Filing on Google Icon
11/5/2025AdvisorShares Investments LLC58,563$0.69M0.1%-13.5%2.484%Search for SEC Filing on Google Icon
8/4/2025AdvisorShares Investments LLC67,733$0.48M0.1%-2.8%3.603%Search for SEC Filing on Google Icon
4/17/2025Cyndeo Wealth Partners LLC10,000$58K0.0%N/A0.569%Search for SEC Filing on Google Icon
2/14/2025Jane Street Group LLC13,311$46K0.0%N/A0.817%Search for SEC Filing on Google Icon
2/14/2025Lynx1 Capital Management LP45,806$0.16M0.1%N/A2.810%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Neuphoria Therapeutics logo
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Read More on Neuphoria Therapeutics

Today's Range

Now: $4.39
Low: $4.30
High: $4.44

50 Day Range

MA: $4.02
Low: $3.72
High: $4.42

52 Week Range

Now: $4.39
Low: $3.64
High: $21.40

Volume

17,131 shs

Average Volume

26,874 shs

Market Capitalization

$23.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Who are the company insiders with the largest holdings of Neuphoria Therapeutics?

Neuphoria Therapeutics' top insider investors include:
  1. Lynx1 Capital Management Lp (Major Shareholder)
Learn More about top insider investors at Neuphoria Therapeutics.

Who are the major institutional investors of Neuphoria Therapeutics?

Neuphoria Therapeutics' top institutional shareholders include:
  1. AdvisorShares Investments LLC — 2.49%
  2. Diadema Partners LP — 0.93%
  3. Ikarian Capital LLC — 0.88%
  4. ADAR1 Capital Management LLC — 0.56%
  5. FNY Investment Advisers LLC — 0.49%
  6. Geode Capital Management LLC — 0.32%
Learn More about top institutional investors of Neuphoria Therapeutics stock.

Which major investors are buying Neuphoria Therapeutics stock?

Within the previous quarter, NEUP stock was bought by institutional investors including:
  1. AdvisorShares Investments LLC
  2. Ikarian Capital LLC
  3. ADAR1 Capital Management LLC
  4. Diadema Partners LP
  5. FNY Investment Advisers LLC
  6. Bridgeway Capital Management LLC
  7. Boothbay Fund Management LLC
  8. XTX Topco Ltd